SCHEMBL7609075

SCHEMBL7609075

COC(=O)c1ccc(NC(=O)[C@H](CC(C)C)NC(=O)C(CC(=O)O)c2cccs2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 4/20 0.56
MMP1 P03956 1/20 0.56
MMP7 P09237 1/20 0.56
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
FCER2 P06734 1/20 0.40
CAPN1 P07384 1/20 0.39
HSPA5 P11021 1/20 0.39
HSPA2 P54652 1/20 0.39
ANPEP P15144 1/20 0.39
HPGD P15428 1/20 0.39
MMP2 P08253 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7612289 1.00 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7763103 1.00 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7604865 1.00 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7403919 0.88 MMP1 (0.52) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7403920 0.88 MMP1 (0.52) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7762371 0.85 MMP3 (0.61) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7764954 0.83 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7605447 0.83 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7605453 0.83 MMP3 (0.56) MMP3MMP1MMP7L3MBTL1ALDH1A1
SCHEMBL7402056 0.81 MMP3 (0.42) MMP3MMP1MMP7L3MBTL1CAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6495699-B2 ANTIARTHRITIC AGENTS; OSTEOPOROSIS AGOURON PHARMACEUTICALS INC. 2002-12-17 US disclosed
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use BENDER STEVEN L (US) 2002-02-14 US disclosed
US-6306892-B1 ENZYME INHIBITORS HETEROCYCLIC AMIDES AGOURON PHARMACEUTICALS, INC. 2001-10-23 US disclosed
US-6174915-B1 FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY AGOURON PHARMACEUTICALS, INC. 2001-01-16 US disclosed
US-6008243-A AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES AGOURON PHARMACEUTICALS, INC. (US) 1999-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use MMP9, MMP2, MMP3 MMP3 3/4885MMP1 8/4885MMP7 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.